[SCHEDULE 13G/A] Instil Bio, Inc. SEC Filing
Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P. reported beneficial ownership of 292,743 shares of Instil Bio, Inc. common stock, equal to 4.5% of the company based on 6,559,927 shares outstanding as disclosed May 9, 2025. The shares are held of record by Vivo Capital Fund IX, L.P., and Vivo Capital IX, LLC is the fund's general partner.
The Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, shows the reporting persons have sole voting and dispositive power over the 292,743 shares and includes a certification that the position was not acquired to change or influence control. The filing is signed by Frank Kung on 08/12/2025.
Vivo Capital IX, LLC e Vivo Capital Fund IX, L.P. hanno dichiarato la titolarit脿 beneficiaria di 292,743 azioni delle azioni ordinarie di Instil Bio, Inc., pari al 4.5% della societ脿 sulla base di 6,559,927 azioni in circolazione come comunicato il 9 maggio 2025. Le azioni risultano registrate a nome di Vivo Capital Fund IX, L.P., e Vivo Capital IX, LLC 猫 il general partner del fondo.
Il Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, indica che i soggetti che effettuano la segnalazione detengono il pieno potere di voto e di disposizione sulle 292,743 azioni e include una certificazione che la posizione non 猫 stata acquisita per modificare o influenzare il controllo. Il deposito 猫 firmato da Frank Kung in data 08/12/2025.
Vivo Capital IX, LLC y Vivo Capital Fund IX, L.P. comunicaron la titularidad beneficiaria de 292,743 acciones de acciones ordinarias de Instil Bio, Inc., equivalentes al 4.5% de la compa帽铆a, con base en 6,559,927 acciones en circulaci贸n seg煤n se divulg贸 el 9 de mayo de 2025. Las acciones est谩n inscritas a nombre de Vivo Capital Fund IX, L.P., y Vivo Capital IX, LLC es la sociedad gestora del fondo.
El Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, indica que las personas informantes tienen el poder exclusivo de voto y de disposici贸n sobre las 292,743 acciones e incluye una certificaci贸n de que la posici贸n no fue adquirida para cambiar o influir en el control. La presentaci贸n est谩 firmada por Frank Kung el 08/12/2025.
Vivo Capital IX, LLC鞕� Vivo Capital Fund IX, L.P.電� Instil Bio, Inc. 氤错喌欤� 292,743欤�鞚� 鞁れ鞝� 靻岇湢毳� 鞁犼碃頄堨溂氅�, 鞚措姅 2025雲� 5鞗� 9鞚� 瓿奠嫓霅� 6,559,927欤检潣 鞙犿喌 欤检嫕靾橂ゼ 旮办鞙茧 須岇偓 歆�攵勳潣 4.5%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 欤检嫕鞚� Vivo Capital Fund IX, L.P. 氇呾潣搿� 霌膘灛霅橃柎 鞛堨溂氅�, Vivo Capital IX, LLC電� 頃措嫻 韼�霌滌潣 鞚茧皹 韺岉姼雱堨瀰雼堧嫟.
Schedule 13G/A (Amendment No. 2), CUSIP 45783C200鞐� 霐半ゴ氅� 氤搓碃鞚鸽摛鞚� 292,743欤检棎 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚� 歆�攵勳澊 瓴届榿甓岇潉 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃橂姅 歃濍獏鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖 靹滊電� 08/12/2025鞐� Frank Kung鞚� 靹滊獏頄堨姷雼堧嫟.
Vivo Capital IX, LLC et Vivo Capital Fund IX, L.P. ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 292,743 actions d'actions ordinaires d'Instil Bio, Inc., soit 4,5% de la soci茅t茅, sur la base de 6,559,927 actions en circulation telle que divulgu茅e le 9 mai 2025. Les actions sont inscrites au nom de Vivo Capital Fund IX, L.P., et Vivo Capital IX, LLC est la soci茅t茅 g茅n茅rale du fonds.
Le Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, indique que les personnes d茅clarantes disposent du pouvoir exclusif de vote et de disposition sur les 292,743 actions et comprend une attestation que la position n'a pas 茅t茅 acquise pour modifier ou influencer le contr么le. Le dossier est sign茅 par Frank Kung le 08/12/2025.
Vivo Capital IX, LLC und Vivo Capital Fund IX, L.P. meldeten die wirtschaftliche Eigent眉merschaft an 292,743 Aktien der Stammaktien von Instil Bio, Inc., was 4,5% des Unternehmens entspricht, basierend auf 6,559,927 ausstehenden Aktien, wie am 9. Mai 2025 offengelegt. Die Aktien sind auf Vivo Capital Fund IX, L.P. eingetragen, und Vivo Capital IX, LLC ist der Generalpartner des Fonds.
Das Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, weist aus, dass die meldepflichtigen Personen 眉ber die 292,743 Aktien alleinige Stimm- und Verf眉gungsgewalt haben und enth盲lt eine Best盲tigung, dass die Position nicht erworben wurde, um die Kontrolle zu 盲ndern oder zu beeinflussen. Die Einreichung ist von Frank Kung am 08/12/2025 unterschrieben.
- Disclosure of a 4.5% stake (292,743 shares) provides transparency to the market
- Sole voting and dispositive power over the reported shares clarifies who controls voting and disposition
- Certification states the position was not acquired to change or influence control, indicating passive intent
- Stake is below 5%, limiting the reporting persons' ability to effect control or trigger more intrusive disclosures
- No shared voting power reported, suggesting no coordinated group that might increase influence
Insights
TL;DR: A small but clear passive stake of 4.5% with sole voting and dispositive power; limited immediate market impact.
The filing documents a 292,743-share holding representing 4.5% of Instil Bio based on 6,559,927 shares outstanding. Because the reporting persons state sole voting and dispositive power for these shares, they control voting and disposition of this block even though the stake is below typical activist thresholds. Item 10's certification explicitly states the position was not acquired to influence control, which aligns with a passive investor disclosure profile. For investors, this is a notable minority position but not a change-of-control event.
TL;DR: Schedule 13G/A shows passive ownership with formal certification of non-control intent; governance implications are limited.
The report identifies Vivo Capital Fund IX, L.P. as record holder and Vivo Capital IX, LLC as its general partner, with sole voting and dispositive authority over 292,743 shares. The filing includes a certification that the securities were not acquired to influence control, indicating no immediate governance initiative disclosed. Because the position is 4.5%, it remains a minority stake; the filing enhances transparency but does not, by itself, change board composition or control rights.
Vivo Capital IX, LLC e Vivo Capital Fund IX, L.P. hanno dichiarato la titolarit脿 beneficiaria di 292,743 azioni delle azioni ordinarie di Instil Bio, Inc., pari al 4.5% della societ脿 sulla base di 6,559,927 azioni in circolazione come comunicato il 9 maggio 2025. Le azioni risultano registrate a nome di Vivo Capital Fund IX, L.P., e Vivo Capital IX, LLC 猫 il general partner del fondo.
Il Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, indica che i soggetti che effettuano la segnalazione detengono il pieno potere di voto e di disposizione sulle 292,743 azioni e include una certificazione che la posizione non 猫 stata acquisita per modificare o influenzare il controllo. Il deposito 猫 firmato da Frank Kung in data 08/12/2025.
Vivo Capital IX, LLC y Vivo Capital Fund IX, L.P. comunicaron la titularidad beneficiaria de 292,743 acciones de acciones ordinarias de Instil Bio, Inc., equivalentes al 4.5% de la compa帽铆a, con base en 6,559,927 acciones en circulaci贸n seg煤n se divulg贸 el 9 de mayo de 2025. Las acciones est谩n inscritas a nombre de Vivo Capital Fund IX, L.P., y Vivo Capital IX, LLC es la sociedad gestora del fondo.
El Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, indica que las personas informantes tienen el poder exclusivo de voto y de disposici贸n sobre las 292,743 acciones e incluye una certificaci贸n de que la posici贸n no fue adquirida para cambiar o influir en el control. La presentaci贸n est谩 firmada por Frank Kung el 08/12/2025.
Vivo Capital IX, LLC鞕� Vivo Capital Fund IX, L.P.電� Instil Bio, Inc. 氤错喌欤� 292,743欤�鞚� 鞁れ鞝� 靻岇湢毳� 鞁犼碃頄堨溂氅�, 鞚措姅 2025雲� 5鞗� 9鞚� 瓿奠嫓霅� 6,559,927欤检潣 鞙犿喌 欤检嫕靾橂ゼ 旮办鞙茧 須岇偓 歆�攵勳潣 4.5%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 欤检嫕鞚� Vivo Capital Fund IX, L.P. 氇呾潣搿� 霌膘灛霅橃柎 鞛堨溂氅�, Vivo Capital IX, LLC電� 頃措嫻 韼�霌滌潣 鞚茧皹 韺岉姼雱堨瀰雼堧嫟.
Schedule 13G/A (Amendment No. 2), CUSIP 45783C200鞐� 霐半ゴ氅� 氤搓碃鞚鸽摛鞚� 292,743欤检棎 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚� 歆�攵勳澊 瓴届榿甓岇潉 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃橂姅 歃濍獏鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖 靹滊電� 08/12/2025鞐� Frank Kung鞚� 靹滊獏頄堨姷雼堧嫟.
Vivo Capital IX, LLC et Vivo Capital Fund IX, L.P. ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 292,743 actions d'actions ordinaires d'Instil Bio, Inc., soit 4,5% de la soci茅t茅, sur la base de 6,559,927 actions en circulation telle que divulgu茅e le 9 mai 2025. Les actions sont inscrites au nom de Vivo Capital Fund IX, L.P., et Vivo Capital IX, LLC est la soci茅t茅 g茅n茅rale du fonds.
Le Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, indique que les personnes d茅clarantes disposent du pouvoir exclusif de vote et de disposition sur les 292,743 actions et comprend une attestation que la position n'a pas 茅t茅 acquise pour modifier ou influencer le contr么le. Le dossier est sign茅 par Frank Kung le 08/12/2025.
Vivo Capital IX, LLC und Vivo Capital Fund IX, L.P. meldeten die wirtschaftliche Eigent眉merschaft an 292,743 Aktien der Stammaktien von Instil Bio, Inc., was 4,5% des Unternehmens entspricht, basierend auf 6,559,927 ausstehenden Aktien, wie am 9. Mai 2025 offengelegt. Die Aktien sind auf Vivo Capital Fund IX, L.P. eingetragen, und Vivo Capital IX, LLC ist der Generalpartner des Fonds.
Das Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, weist aus, dass die meldepflichtigen Personen 眉ber die 292,743 Aktien alleinige Stimm- und Verf眉gungsgewalt haben und enth盲lt eine Best盲tigung, dass die Position nicht erworben wurde, um die Kontrolle zu 盲ndern oder zu beeinflussen. Die Einreichung ist von Frank Kung am 08/12/2025 unterschrieben.
FAQ
What stake in Instil Bio (TIL) did Vivo Capital report?
Does the filing indicate Vivo Capital intends to take control of Instil Bio (TIL)?
Who holds the shares of Instil Bio for Vivo Capital?
What voting and disposition powers are reported?
What document and CUSIP record this ownership?
When was the Schedule 13G/A signed?
